Deals channel feed – Endpoints News

Deals channel feed

Daniel O’Day’s I/O dance continues, as Gilead and Tango expand deal up to $6B

5 years ago

Blackstone finalizes R&D pact with Alnylam as part of earlier $2 billion investment

5 years ago

Taysha buys clinic-ready gene therapy from Abeona, bringing Steven Gray's portfolio back in one place

5 years ago

Bristol Myers bets $475M cash on a blockbuster shot at breaking the mold in immuno-oncology — with a potential IL-12 game-changer

5 years ago

How badly does Sanofi chief Paul Hudson want Principia? Enough to ink a $3.7B buyout deal, doubling down on MS

5 years ago

Eyeing in-vivo editing, Mammoth licenses Jennifer Doudna’s new CRISPR enzyme

5 years ago

Calliditas bets up to $102M on a biotech buyout, snagging a once-failed PBC drug

5 years ago

Qiagen investors spurn Thermo Fisher’s takeover offer, derailing a $12B+ deal

5 years ago

Galaxy Life Sciences lands $50 million deal to build in central Massachusetts biomanufacturing park

5 years ago

Novartis’ CAR-T partner in China wraps $383M take-private deal engineered by CEO

5 years ago

Roche pulls a tumor micro-environment drug out of the freezer, hands it to a UK upstart

5 years ago

Perceptive births its first in-house startup — and it's a China play

5 years ago

Ligand scoops up Pfenex for up to $516M, adding proteins to their antibody chickens and delivery tech

5 years ago

Hunting a blockbuster, Bayer forges an $875M-plus M&A deal to acquire women’s health biotech

5 years ago

The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline

5 years ago

Biohaven adds nearly $1B in Nurtec deals with Royalty Pharma, Sixth Street

5 years ago

AbbVie abandons a pioneering CRISPR R&D alliance with Editas as Brent Saunders' deal is cast out

5 years ago

Biogen hands Denali $1B-plus in cash, $1B-plus in milestones to partner on late-stage Parkinson’s drug

5 years ago

Stem cell player ViaCyte expands collaboration with Gore to develop subcutaneous diabetes treatment

5 years ago

Merck scoops up a PhII J&J discard in a bargain-basement deal. And this time they’re shooting at NASH

5 years ago

AstraZeneca throws Redx a lifeline — in exchange for a preclinical fibrosis drug — with a promise of $17M in quick cash plus milestones

5 years ago

Sanofi and GSK say they're near a vaccine deal with EU hours after finalizing Warp Speed contract

5 years ago

Novartis turns to Sangamo with a $795M-plus deal aimed at using zinc finger tech for the neuro pipeline

5 years ago

F-star's Eliot Forster maps a shortcut to Wall Street, bagging more cash to fuel oncology pipeline work

5 years ago

First page Previous page 87 88 899091 92 93 Next page Last page